<DOC>
	<DOCNO>NCT01399593</DOCNO>
	<brief_summary>The purpose trial determine safety efficacy eculizumab prevention antibody mediate rejection ( AMR ) live donor kidney recipient require desensitization therapy .</brief_summary>
	<brief_title>Safety &amp; Efficacy Eculizumab Prevent AMR Living Donor Kidney Transplant Recipients Requiring Desensitization</brief_title>
	<detailed_description />
	<criteria>1 . Male female patient â‰¥18 year old 2 . Patients Stage IV Stage V chronic kidney disease receive kidney transplant live donor sensitized require desensitization prior transplantation 3 . Able understand inform consent form willing comply study procedures 1 . Hypersensitivity eculizumab , murine proteins one excipients 2 . Any medical condition , opinion Investigator , might interfere patient 's participation study , pose added risk patient , confound assessment patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Antibody Mediated Rejection</keyword>
	<keyword>AMR</keyword>
	<keyword>Acute Humoral Rejection</keyword>
	<keyword>AHR</keyword>
	<keyword>Living Donor</keyword>
	<keyword>Kidney Transplant</keyword>
</DOC>